000			01907na a2200229 4500
003			PC4986
005			20180417114631.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_9876 _aAguado García, José María _eEnfermedades Infecciosas
245	0	0	_aProfilaxis de la infección por citomegalovirus en el trasplante renal _h[artículo]
260			_bEnfermedades Infecciosas y Microbiología Clínica, _c2011
300			_a29(Suppl 6):38-41.
500			_aFormato Vancouver: Aguado JM, Gil Vernet S. Profilaxis de la infección por citomegalovirus en el trasplante renal. Enferm Infecc Microbiol Clin. 2011;29 Suppl 6:38-41.
501			_aPMID: 22541921
504			_aContiene 25 referencias.
520			_2Cytomegalovirus (CMV) infection remains a major problem in renal transplant recipients. CMV produces not only febrile syndromes and/or visceral disease but also contributes to the development of acute rejection and chronic graft failure. Valganciclovir prophylaxis has represented a major advance in controlling this infection, but late CMV infection after prophylaxis can occur, especially when universal prophylaxis is used. The use of valganciclovir prophylaxis for 200 days is more effective than prophylaxis for 100 days but does not completely prevent this problem. Prophylaxis based on the detection of CMV viremia (early prophylaxis or preemptive therapy) may prevent the development of delayed CMV disease, but has the disadvantage of requiring more intensive monitoring of viremia and does not prevent the development of viremia and its potential consequences in the long term. This article reviews current recommendations for prophylaxis of CMV disease in renal transplantation.
710			_96 _aServicio de Medicina Interna
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc4986.pdf _ySolicitar documento
942			_2ddc _cART _n0
999			_c4986 _d4986